BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Disc Medicine readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Disc Medicine's drugs run\, from 
 ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05320198-928@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Selcodebart: Phase 1/2 readout est. (NCT05320198)
DESCRIPTION:Selcodebart\, phase 1/2\, Anemia of Myelofibrosis.\nStudy: Stud
 y of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodyspl
 astic Syndrome and Anemia\nEstimated primary completion: May 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/selcodebart#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05320198
URL:https://assetmemo.bio/drug/selcodebart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06985147-10341@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:DISC-3405: Phase 2 readout est. (NCT06985147)
DESCRIPTION:DISC-3405\, phase 2\, Polycythemia Vera.\nStudy: A Phase 2\, Op
 en-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)\nE
 stimated primary completion: July 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/disc-3405#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06985147
URL:https://assetmemo.bio/drug/disc-3405#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05883748-9334@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Bitopertin: Phase 2/3 readout est. (NCT05883748)
DESCRIPTION:Bitopertin\, phase 2/3\, Erythropoietic Protoporphyria.\nStudy:
  HELIOS: Open-Label\, Long-Term Extension Study to Investigate the Safety\
 , Tolerability\, and Efficacy of DISC-1459 (Bitopertin) in Participants Wi
 th EPP or XLP\nEstimated primary completion: June 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/bitopertin#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05883748
URL:https://assetmemo.bio/drug/bitopertin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
